European Myeloma Network B.v.

This study tests whether adding the drug teclistamab to standard maintenance therapy (lenalidomide) can help keep multiple myeloma from coming back after a stem cell transplant. About 1,600 adults with newly diagnosed myeloma who have already responded to initial treatment will b…

This study tests a drug called teclistamab in 30 people with AL amyloidosis, a rare disease where abnormal proteins damage organs. Participants have already had other treatments. The goal is to see if teclistamab can reduce or eliminate the harmful proteins in the blood. The stud…

This study tests two drug combinations (teclistamab plus daratumumab or talquetamab plus daratumumab) in 150 frail patients newly diagnosed with multiple myeloma. The goal is to see if these fixed-duration treatments can control the cancer for at least 18 months. Participants rec…

This phase 3 study is testing whether adding the experimental drug linvoseltamab after initial treatment can improve outcomes for people newly diagnosed with multiple myeloma who are not eligible for a stem cell transplant. About 1,000 participants will receive either standard th…

This study collects and stores blood and tissue samples from 6,000 people with multiple myeloma and related conditions like smoldering myeloma and MGUS. The goal is to create a shared resource for researchers worldwide to study these diseases and improve patient care. Participant…